View ValuationHarbin Pharmaceutical Group 将来の成長Future 基準チェック /26Harbin Pharmaceutical Group利益と収益がそれぞれ年間21.3%と3.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に8.3% 22.1%なると予測されています。主要情報21.3%収益成長率22.15%EPS成長率Pharmaceuticals 収益成長16.1%収益成長率3.3%将来の株主資本利益率8.26%アナリストカバレッジLow最終更新日17 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Aug 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Profit margins are more than 30% lower than last year (1.9% net profit margin).Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improves as stock rises 26%After last week's 26% share price gain to CN¥6.77, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 100% over the past three years.Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥3.71, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 16% over the past three years.お知らせ • Jun 30Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026お知らせ • Jun 03Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 23, 2026Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 23, 2026, at 13:30 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang ChinaBoard Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Ying Lei was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • Mar 30Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Dec 26Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Harbin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026お知らせ • Sep 30Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025お知らせ • Jun 30Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025お知らせ • May 30Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 20, 2025Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 20, 2025, at 14:00 China Standard Time.お知らせ • Mar 28Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025お知らせ • Dec 27Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025Reported Earnings • Oct 26Third quarter 2024 earnings released: EPS: CN¥0.061 (vs CN¥0.053 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.061 (up from CN¥0.053 in 3Q 2023). Revenue: CN¥4.11b (up 8.5% from 3Q 2023). Net income: CN¥164.9m (up 53% from 3Q 2023). Profit margin: 4.0% (up from 2.8% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 22%After last week's 22% share price gain to CN¥3.75, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total returns to shareholders of 10.0% over the past three years.お知らせ • Sep 30Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.022 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.07 (up from CN¥0.022 in 2Q 2023). Revenue: CN¥4.00b (up 6.1% from 2Q 2023). Net income: CN¥166.6m (up 176% from 2Q 2023). Profit margin: 4.2% (up from 1.6% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Board Change • Aug 02High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Chairman Xiaoping Hu is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥3.07, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 2.8% over the past three years.お知らせ • Jun 28Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 23, 2024お知らせ • May 18Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang ChinaReported Earnings • Apr 12Full year 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.19 in FY 2022)Full year 2023 results: EPS: CN¥0.16 (down from CN¥0.19 in FY 2022). Revenue: CN¥15.5b (up 12% from FY 2022). Net income: CN¥395.3m (down 15% from FY 2022). Profit margin: 2.6% (down from 3.4% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 29Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • Feb 05Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥2.50, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 2.9% over the past three years.お知らせ • Dec 29Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 11, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 11, 2024Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.053 (vs CN¥0.012 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.053 (up from CN¥0.012 in 3Q 2022). Revenue: CN¥3.79b (up 6.0% from 3Q 2022). Net income: CN¥107.8m (up 213% from 3Q 2022). Profit margin: 2.8% (up from 1.0% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 30Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023Reported Earnings • Aug 25Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.022 (up from CN¥0.009 in 2Q 2022). Revenue: CN¥3.77b (up 22% from 2Q 2022). Net income: CN¥60.4m (up 180% from 2Q 2022). Profit margin: 1.6% (up from 0.7% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 12Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.15 in FY 2021)Full year 2022 results: EPS: CN¥0.19 (up from CN¥0.15 in FY 2021). Revenue: CN¥13.8b (up 7.9% from FY 2021). Net income: CN¥464.4m (up 25% from FY 2021). Profit margin: 3.4% (up from 2.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Reported Earnings • Jan 14Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in FY 2021)Full year 2022 results: EPS: CN¥0.17 (up from CN¥0.15 in FY 2021). Revenue: CN¥13.9b (up 8.5% from FY 2021). Net income: CN¥430.6m (up 16% from FY 2021). Profit margin: 3.1% (up from 2.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 4 independent directors (8 non-independent directors). Independent Director Fu Wang was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.012 (vs CN¥0.06 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.012 (down from CN¥0.06 in 3Q 2021). Revenue: CN¥3.57b (up 7.2% from 3Q 2021). Net income: CN¥34.4m (down 76% from 3Q 2021). Profit margin: 1.0% (down from 4.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 27Second quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.12 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.009 (down from CN¥0.12 in 2Q 2021). Revenue: CN¥3.08b (down 10.0% from 2Q 2021). Net income: CN¥21.6m (down 92% from 2Q 2021). Profit margin: 0.7% (down from 7.6% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.03 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.04 (up from CN¥0.03 in 1Q 2021). Revenue: CN¥3.33b (up 12% from 1Q 2021). Net income: CN¥100.4m (up 21% from 1Q 2021). Profit margin: 3.0% (up from 2.8% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Director Fu Wang was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 10Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.43 loss in FY 2020)Full year 2021 results: EPS: CN¥0.15 (up from CN¥0.43 loss in FY 2020). Revenue: CN¥12.8b (up 19% from FY 2020). Net income: CN¥371.1m (up CN¥1.45b from FY 2020). Profit margin: 2.9% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.Reported Earnings • Oct 26Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.014 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥3.33b (up 17% from 3Q 2020). Net income: CN¥144.4m (up CN¥183.8m from 3Q 2020). Profit margin: 4.3% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.06 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥3.43b (up 49% from 2Q 2020). Net income: CN¥259.2m (up CN¥405.9m from 2Q 2020). Profit margin: 7.6% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 116 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.07 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.98b (up 19% from 1Q 2020). Net income: CN¥82.9m (up CN¥269.5m from 1Q 2020). Profit margin: 2.8% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 03Full year 2020 earnings released: CN¥0.43 loss per share (vs CN¥0.02 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: CN¥10.8b (down 8.8% from FY 2019). Net loss: CN¥1.08b (down CN¥1.13b from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Jan 25New 90-day low: CN¥2.84The company is down 15% from its price of CN¥3.36 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period.Is New 90 Day High Low • Jan 07New 90-day low: CN¥3.09The company is down 11% from its price of CN¥3.47 on 09 October 2020. The Chinese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.Is New 90 Day High Low • Dec 14New 90-day low: CN¥3.22The company is down 6.0% from its price of CN¥3.43 on 16 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 6.0% over the same period.Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total losses of CN¥321.1m, with earnings decreasing by CN¥428.0m from the prior year. Total revenue was CN¥11.0b over the last 12 months, down 1.5% from the prior year.Is New 90 Day High Low • Oct 29New 90-day low: CN¥3.33The company is down 6.0% from its price of CN¥3.53 on 31 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 9.0% over the same period.業績と収益の成長予測XSSC:600664 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202817,491602N/A986112/31/202716,939520N/A1,009112/31/202616,403452N/A68813/31/202615,965310566718N/A12/31/202515,964362289440N/A9/30/202515,941449173280N/A6/30/202516,158545467578N/A3/31/202516,208665493599N/A12/31/202416,176629692792N/A9/30/202416,219613210323N/A6/30/202415,895556400492N/A3/31/202415,667450411496N/A12/31/202315,457395863950N/A9/30/202315,3125991,2181,284N/A6/30/202315,096526925988N/A3/31/202314,406487576650N/A12/31/202213,809465532622N/A9/30/202213,0534134137N/A6/30/202212,812151-252-157N/A3/31/202213,15638973166N/A12/31/202112,802371-239-162N/A9/30/202112,879-219-903-811N/A6/30/202112,385-402-511-402N/A3/31/202111,258-808-1,015-902N/A12/31/202010,788-1,078-846-728N/A9/30/202011,009-321-289-209N/A6/30/202011,118-235-334-271N/A3/31/202011,66114-162-107N/A12/31/201911,82556N/A-285N/A9/30/201911,174107N/A390N/A6/30/201910,696-59N/A418N/A3/31/201910,63061N/A372N/A12/31/201810,814346N/A693N/A9/30/201810,910386N/A197N/A6/30/201811,484422N/A-36N/A3/31/201811,790501N/A202N/A12/31/201712,018407N/A149N/A9/30/201712,993441N/A598N/A6/30/201713,180757N/A1,110N/A3/31/201713,761737N/A1,833N/A12/31/201614,127788N/A2,778N/A9/30/201613,662789N/A3,179N/A6/30/201613,830584N/A3,553N/A3/31/201614,435515N/A2,929N/A12/31/201515,856580N/A1,660N/A9/30/201516,038324N/A899N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 600664の予測収益成長率 (年間21.3% ) は 貯蓄率 ( 2.4% ) を上回っています。収益対市場: 600664の収益 ( 21.3% ) CN市場 ( 26.3% ) よりも低い成長が予測されています。高成長収益: 600664の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: 600664の収益 ( 3.3% ) CN市場 ( 16.9% ) よりも低い成長が予測されています。高い収益成長: 600664の収益 ( 3.3% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 600664の 自己資本利益率 は、3年後には低くなると予測されています ( 8.3 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/24 16:57終値2026/08/24 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Harbin Pharmaceutical Group Co., Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Wayne HeChina Stock Investment Research Co. Ltd. (DeepValue.online)null Research DepartmentGuotai Haitong/Guotai Junan International Holdings LimitedWen DaiHuatai Research1 その他のアナリストを表示
New Risk • Aug 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Profit margins are more than 30% lower than last year (1.9% net profit margin).
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improves as stock rises 26%After last week's 26% share price gain to CN¥6.77, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 100% over the past three years.
Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥3.71, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 16% over the past three years.
お知らせ • Jun 30Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026
お知らせ • Jun 03Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 23, 2026Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 23, 2026, at 13:30 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang China
Board Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Ying Lei was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • Mar 30Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Dec 26Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Harbin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026
お知らせ • Sep 30Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025
お知らせ • Jun 30Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025
お知らせ • May 30Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 20, 2025Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 20, 2025, at 14:00 China Standard Time.
お知らせ • Mar 28Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025
お知らせ • Dec 27Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025Harbin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025
Reported Earnings • Oct 26Third quarter 2024 earnings released: EPS: CN¥0.061 (vs CN¥0.053 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.061 (up from CN¥0.053 in 3Q 2023). Revenue: CN¥4.11b (up 8.5% from 3Q 2023). Net income: CN¥164.9m (up 53% from 3Q 2023). Profit margin: 4.0% (up from 2.8% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 22%After last week's 22% share price gain to CN¥3.75, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total returns to shareholders of 10.0% over the past three years.
お知らせ • Sep 30Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024
Reported Earnings • Aug 23Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.022 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.07 (up from CN¥0.022 in 2Q 2023). Revenue: CN¥4.00b (up 6.1% from 2Q 2023). Net income: CN¥166.6m (up 176% from 2Q 2023). Profit margin: 4.2% (up from 1.6% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Board Change • Aug 02High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Chairman Xiaoping Hu is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥3.07, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 2.8% over the past three years.
お知らせ • Jun 28Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 23, 2024
お知らせ • May 18Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024Harbin Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 07, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang China
Reported Earnings • Apr 12Full year 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.19 in FY 2022)Full year 2023 results: EPS: CN¥0.16 (down from CN¥0.19 in FY 2022). Revenue: CN¥15.5b (up 12% from FY 2022). Net income: CN¥395.3m (down 15% from FY 2022). Profit margin: 2.6% (down from 3.4% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 29Harbin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • Feb 05Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥2.50, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 2.9% over the past three years.
お知らせ • Dec 29Harbin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 11, 2024Harbin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 11, 2024
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.053 (vs CN¥0.012 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.053 (up from CN¥0.012 in 3Q 2022). Revenue: CN¥3.79b (up 6.0% from 3Q 2022). Net income: CN¥107.8m (up 213% from 3Q 2022). Profit margin: 2.8% (up from 1.0% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 30Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
Reported Earnings • Aug 25Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.022 (up from CN¥0.009 in 2Q 2022). Revenue: CN¥3.77b (up 22% from 2Q 2022). Net income: CN¥60.4m (up 180% from 2Q 2022). Profit margin: 1.6% (up from 0.7% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 12Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.15 in FY 2021)Full year 2022 results: EPS: CN¥0.19 (up from CN¥0.15 in FY 2021). Revenue: CN¥13.8b (up 7.9% from FY 2021). Net income: CN¥464.4m (up 25% from FY 2021). Profit margin: 3.4% (up from 2.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Reported Earnings • Jan 14Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in FY 2021)Full year 2022 results: EPS: CN¥0.17 (up from CN¥0.15 in FY 2021). Revenue: CN¥13.9b (up 8.5% from FY 2021). Net income: CN¥430.6m (up 16% from FY 2021). Profit margin: 3.1% (up from 2.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 4 independent directors (8 non-independent directors). Independent Director Fu Wang was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.012 (vs CN¥0.06 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.012 (down from CN¥0.06 in 3Q 2021). Revenue: CN¥3.57b (up 7.2% from 3Q 2021). Net income: CN¥34.4m (down 76% from 3Q 2021). Profit margin: 1.0% (down from 4.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 27Second quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.12 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.009 (down from CN¥0.12 in 2Q 2021). Revenue: CN¥3.08b (down 10.0% from 2Q 2021). Net income: CN¥21.6m (down 92% from 2Q 2021). Profit margin: 0.7% (down from 7.6% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
Reported Earnings • Apr 29First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.03 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.04 (up from CN¥0.03 in 1Q 2021). Revenue: CN¥3.33b (up 12% from 1Q 2021). Net income: CN¥100.4m (up 21% from 1Q 2021). Profit margin: 3.0% (up from 2.8% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Director Fu Wang was the last independent director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 10Full year 2021 earnings released: EPS: CN¥0.15 (vs CN¥0.43 loss in FY 2020)Full year 2021 results: EPS: CN¥0.15 (up from CN¥0.43 loss in FY 2020). Revenue: CN¥12.8b (up 19% from FY 2020). Net income: CN¥371.1m (up CN¥1.45b from FY 2020). Profit margin: 2.9% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
Reported Earnings • Oct 26Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.014 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥3.33b (up 17% from 3Q 2020). Net income: CN¥144.4m (up CN¥183.8m from 3Q 2020). Profit margin: 4.3% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.06 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥3.43b (up 49% from 2Q 2020). Net income: CN¥259.2m (up CN¥405.9m from 2Q 2020). Profit margin: 7.6% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 116 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.07 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.98b (up 19% from 1Q 2020). Net income: CN¥82.9m (up CN¥269.5m from 1Q 2020). Profit margin: 2.8% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 03Full year 2020 earnings released: CN¥0.43 loss per share (vs CN¥0.02 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: CN¥10.8b (down 8.8% from FY 2019). Net loss: CN¥1.08b (down CN¥1.13b from profit in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Jan 25New 90-day low: CN¥2.84The company is down 15% from its price of CN¥3.36 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Jan 07New 90-day low: CN¥3.09The company is down 11% from its price of CN¥3.47 on 09 October 2020. The Chinese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Dec 14New 90-day low: CN¥3.22The company is down 6.0% from its price of CN¥3.43 on 16 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 6.0% over the same period.
Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total losses of CN¥321.1m, with earnings decreasing by CN¥428.0m from the prior year. Total revenue was CN¥11.0b over the last 12 months, down 1.5% from the prior year.
Is New 90 Day High Low • Oct 29New 90-day low: CN¥3.33The company is down 6.0% from its price of CN¥3.53 on 31 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 9.0% over the same period.